Post-earnings recap
Reported
Thu, Feb 16, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioCryst Pharmaceuticals reported a loss that was slightly worse than expected, which contributed to a 2.68% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Overall, the market reacted negatively due to uncertainty surrounding upcoming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -1.75% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions affecting performance. They did not provide a clear outlook for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.